| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
C6 Ceramide targets the ceramide pathway, a key signaling pathway involved in cell growth, differentiation, and apoptosis. As a cell-permeable ceramide analog, it activates ceramide-mediated signaling pathways. It induces cell cycle arrest and apoptosis in cancer cells. It can enhance the effects of chemotherapeutic agents, particularly in drug-resistant cancer cells. Its mechanism of action involves modulation of various downstream targets including protein phosphatases, kinases, and death receptors. The compound's short-chain structure allows it to readily enter cells and mimic the effects of natural long-chain ceramides.
|
|---|---|
| ln Vitro |
In vitro, C6 Ceramide has demonstrated anticancer activity against a variety of cancer/tumor cell lines. It induces cell cycle arrest and apoptosis. It inhibits tumor growth. It enhances the effects of chemotherapeutic agents on drug-resistant cancer cells. These activities confirm its potential for cancer research and as an adjuvant to enhance chemotherapy. Its cell-permeable nature makes it a valuable tool for studying ceramide signaling in cell-based assays.
|
| ln Vivo |
In vivo, C6 Ceramide has been studied for its anticancer effects and as an adjuvant to enhance chemotherapy. Its ability to induce apoptosis and inhibit tumor growth has been demonstrated in animal models. However, detailed in vivo efficacy and safety data are described in the primary literature. The compound is primarily used in research applications. Further studies are needed to fully characterize its in vivo therapeutic potential. The compound is intended for research use only and not for human therapeutic applications.
|
| Enzyme Assay |
For in vitro biochemical assays, C6 Ceramide is evaluated for its effects on ceramide signaling and apoptosis. Ceramide pathway activation is assessed by measuring the phosphorylation or activity of downstream targets such as protein phosphatases, kinases, and death receptors. Apoptosis is assessed by measuring caspase activity, DNA fragmentation, and Annexin V binding. Cell cycle analysis is performed using propidium iodide staining and flow cytometry. These cell-free and cell-based assays help characterize the compound's mechanism of action.
|
| Cell Assay |
In vitro cellular assays for C6 Ceramide are performed using various cancer cell lines, including drug-resistant lines. Cells are cultured in standard media and treated with the compound at various concentrations, alone or in combination with chemotherapeutic agents. Cell viability is assessed using MTT or SRB assays. Apoptosis is evaluated by measuring caspase activity, Annexin V/PI staining, and DNA fragmentation. Cell cycle analysis is performed using flow cytometry. Synergy with chemotherapeutic agents is assessed using combination index calculations. These cellular assays help validate the compound's anticancer activity and its potential as a chemotherapy adjuvant.
|
| Animal Protocol |
In vivo animal experiments with C6 Ceramide are conducted in tumor xenograft models. Cancer cells are injected subcutaneously into immunodeficient mice. After tumor establishment, C6 Ceramide is administered alone or in combination with chemotherapeutic agents via various routes including intratumoral injection, intraperitoneal injection, or intravenous injection. Tumor volume and weight are monitored. Endpoint analyses include assessment of apoptosis, cell cycle markers, and tumor growth inhibition. The compound's safety and tolerability are monitored through body weight, clinical signs, and histopathology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of C6 Ceramide have been partially characterized. As a cell-permeable ceramide analog with a molecular weight of 397.6, it is expected to have moderate bioavailability. The compound is more hydrophobic than C2 ceramide and may more closely mimic the effects of natural ceramides. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not extensively documented. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of C6 Ceramide is not extensively characterized. As a ceramide analog, it may have dose-dependent toxicity at high concentrations due to its pro-apoptotic effects. The compound is intended for research use only and not for human therapeutic applications. Comprehensive toxicity studies including acute, subchronic, and chronic toxicity assessments are limited. Researchers should follow standard laboratory safety practices when handling C6 Ceramide. Its effects at high concentrations and potential interactions with other drugs or compounds have not been fully investigated.
|
| Additional Infomation |
N-(hexanoyl)sphingosine-4-ene is an N-acylsphingosine composed of sphingosine-4-ene with a hexanoyl group attached to the nitrogen atom. It is functionally related to sphingosine-4-ene.
C6 Ceramide is a valuable research tool for studying ceramide signaling, apoptosis, and cancer biology. Its cell-permeable nature makes it useful for investigating the role of ceramide in cell growth, differentiation, and death. Its ability to enhance the effects of chemotherapeutic agents on drug-resistant cancer cells provides opportunities for studying combination therapies and overcoming drug resistance. The compound can be employed to study the mechanisms of ceramide-induced apoptosis and to develop new strategies for cancer treatment. Its short-chain structure makes it a useful model for studying ceramide structure-activity relationships. |
| Molecular Formula |
C24H47NO3
|
|---|---|
| Molecular Weight |
397.63500
|
| Exact Mass |
397.355
|
| CAS # |
124753-97-5
|
| Related CAS # |
Ceramide C6-d7; 2692624-22-7
|
| PubChem CID |
5702613
|
| Appearance |
White to off-white solid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
574.7±50.0 °C at 760 mmHg
|
| Melting Point |
76-77ºC
|
| Flash Point |
301.4±30.1 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.483
|
| LogP |
8.02
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
28
|
| Complexity |
371
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCCCCCCCCCC/C=C/[C@@H](O)[C@@H](NC(CCCCC)=O)CO
|
| InChi Key |
NPRJSFWNFTXXQC-QFWQFVLDSA-N
|
| InChi Code |
InChI=1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+/t22-,23+/m0/s1
|
| Chemical Name |
N-[(E,2S,3R)-1,3-dihydroxyoctadec-4-en-2-yl]hexanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~251.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5148 mL | 12.5742 mL | 25.1484 mL | |
| 5 mM | 0.5030 mL | 2.5148 mL | 5.0297 mL | |
| 10 mM | 0.2515 mL | 1.2574 mL | 2.5148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
